Global Antinuclear Antibody Test Market

Antinuclear Antibody Test Market was valued at USD 3.67 Bn. in 2025 and is estimated to grow at a CAGR of 12.4 % over the forecast period.

Antinuclear Antibody Test Market Overview:

The anti-nuclear antibody test (ANA) or FANA (fluorescent anti-nuclear antibody) is a blood test that detects the presence of auto-antibodies in the serum, which are antibodies produced by the body against its own cells. In normal circumstances, the human immune system recognises foreign things such as bacteria, virus, fungus, and other microbes and mounts an immune response against them.

To know about the Research Methodology:-Request Free Sample Report

Antinuclear Antibody Test Market Segment Analysis:

The global Antinuclear Antibody (ANA) Test Market is segmented based on product, technique, disease indication, and end user. By product, reagents & assay kits dominate the market, accounting for the largest revenue share due to their repetitive usage in diagnostic procedures and continuous demand in laboratories. Systems and software & services segments are also growing with increasing automation in diagnostic platforms.

Based on technique, the market is led by the immunofluorescence assay (IFA) segment, which holds the highest share owing to its high sensitivity and status as the gold standard for ANA detection. ELISA and multiplex assays are also gaining traction due to their efficiency and ability to handle high-throughput testing.

By disease indication, rheumatoid arthritis dominates the market, driven by its high global prevalence and increasing geriatric population. Other key segments include systemic lupus erythematosus (SLE), Sjögren’s syndrome, and scleroderma, all contributing significantly due to rising autoimmune disease awareness and early diagnosis trends.

In terms of end users, hospitals account for the largest market share, supported by advanced diagnostic infrastructure, higher patient inflow, and availability of integrated testing facilities. Clinical laboratories and physician office laboratories are also expanding due to increasing outsourcing of diagnostic services.

Antinuclear Antibody Test Market Regional Analysis

Regionally, North America dominates the global Antinuclear Antibody Test Market, holding over 40% revenue share, driven by well-established healthcare infrastructure, high healthcare expenditure, and a strong presence of leading diagnostic companies. The United States contributes significantly due to the high prevalence of autoimmune diseases and early adoption of advanced diagnostic technologies.

Europe represents the second-largest market, supported by increasing awareness of autoimmune disorders, favorable reimbursement policies, and strong healthcare systems across countries such as Germany, the UK, and France.

The Asia-Pacific region is the fastest-growing market, fueled by rising healthcare investments, growing population, and increasing awareness regarding early disease diagnosis in countries like China, India, and Japan. Rapid expansion of diagnostic laboratories and improving healthcare access further boost regional growth.

Recent Industry Developments (2025–2026)

Global Antinuclear Antibody Test Market Scope: Inquire before buying 

Antinuclear Antibody Test Market by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)

Antinuclear Antibody Test Market Key Players

• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• EUROIMMUN AG
• Trinity Biotech plc
• ERBA Diagnostics Inc.
• Ortho Clinical Diagnostics
• Fujirebio Inc.
• BioMérieux SA
• Agilent Technologies Inc.
• PerkinElmer Inc.
• ZEUS Scientific Inc.
• Immuno Concepts Inc.
• Inova Diagnostics Inc.
• Antibodies Inc.
• Alere Inc.
• Randox Laboratories Ltd.
• Sekisui Diagnostics
• Diasorin S.p.A.
• QuidelOrtho Corporation
• Hologic Inc.
• Sysmex Corporation